Nuvectis Pharma, Inc.
NVCT
$9.29
-$0.205-2.16%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.91% | -7.89% | 12.58% | 0.12% | 9.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.94% | -29.21% | -19.56% | 7.19% | 5.16% |
| Operating Income | -9.94% | 29.21% | 19.56% | -7.19% | -5.16% |
| Income Before Tax | 5.65% | 29.38% | 22.42% | -3.01% | 1.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.65% | 29.38% | 22.42% | -3.01% | 1.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.65% | 29.38% | 22.42% | -3.01% | 1.11% |
| EBIT | -9.94% | 29.21% | 19.56% | -7.19% | -5.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 13.92% | 34.01% | 30.34% | 8.40% | 10.49% |
| Normalized Basic EPS | -1.38% | 34.01% | 30.30% | 8.44% | 7.39% |
| EPS Diluted | 13.92% | 34.01% | 30.34% | 8.40% | 10.49% |
| Normalized Diluted EPS | -1.38% | 34.01% | 30.30% | 8.44% | 7.39% |
| Average Basic Shares Outstanding | 9.61% | 6.99% | 11.35% | 12.46% | 10.48% |
| Average Diluted Shares Outstanding | 9.61% | 6.99% | 11.35% | 12.46% | 10.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
